Summary
234.44 0.44(0.19%)11/18/2025
AbbVie Inc. (ABBV)
ABBV reported last earnings on 2025-10-31 after the market. An EPS of $1.86 was observed compared to an estimated EPS of $1.77, resulting in a surprise value of $0.09. A revenue of $15,776 million was observed compared to an estimated revenue of $15,586 million, resulting in a surprise value of $190 Million.
AbbVie Inc. (ABBV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.19 | 3.92 | 1.93 | 14.10 | 28.01 | 45.65 | 188.07 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Strong Buy |
| ROE | Strong Sell |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 234.44 | |
| Open | 235.00 | |
| High | 237.19 | |
| Low | 232.11 | |
| Volume | 4,503,564 | |
| Change | 0.44 | |
| Change % | 0.19 | |
| Avg Volume (20 Days) | 5,581,516 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 159.68 - 243.06 | |
| Price vs 52 Week High | -3.55% | |
| Price vs 52 Week Low | 46.82% | |
| Range | 0.00 | |
| Gap Up/Down | -1.74 | |
Profitibility | ||
| Market Capitalization (Mln) | 383,433 | |
| Revenue per share | 33.6591 | |
| Net Income per share | 1.3510 | |
| Dividend Yield | 0.0280 | |
| Dividend Share | 656.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 173.1068 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
11/18 12:47 EST - prnewswire.com
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2...
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2...
11/18 10:41 EST - zacks.com
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
11/18 09:00 EST - seekingalpha.com
It's Best Time In 10 Years To Lock In Income: Our Picks
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–80% of returns come from the Mag7, leaving broad-market returns near inflation levels. US...
It's Best Time In 10 Years To Lock In Income: Our Picks
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–80% of returns come from the Mag7, leaving broad-market returns near inflation levels. US...
11/17 07:17 EST - fool.com
AbbVie Stock Falls 4% -- What Investors Need to Know
It's no reason to stay up at night.
AbbVie Stock Falls 4% -- What Investors Need to Know
It's no reason to stay up at night.
11/15 07:25 EST - fool.com
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
AbbVie is a Dividend King with a bright future. Enbridge offers an especially dependable dividend.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
AbbVie is a Dividend King with a bright future. Enbridge offers an especially dependable dividend.
11/14 16:31 EST - seekingalpha.com
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript
AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can...
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript
AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can...
11/14 15:19 EST - youtube.com
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
11/14 04:12 EST - defenseworld.net
Arvest Bank Trust Division Sells 323 Shares of AbbVie Inc. $ABBV
Arvest Bank Trust Division decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,971 shares of the company's stock after selling 323 shares during the...
Arvest Bank Trust Division Sells 323 Shares of AbbVie Inc. $ABBV
Arvest Bank Trust Division decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,971 shares of the company's stock after selling 323 shares during the...
11/13 16:02 EST - gurufocus.com
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
11/13 08:30 EST - prnewswire.com
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living...
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living...
11/13 08:10 EST - 247wallst.com
Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.
Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.
11/12 15:06 EST - benzinga.com
AbbVie Shares Rise To Intraday High After Key Trading Signal
AbbVie Inc (NYSE:ABBV) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.At 10:04 AM EST on November 12, ABBV triggered a Power Inflow signal at a price of...
AbbVie Shares Rise To Intraday High After Key Trading Signal
AbbVie Inc (NYSE:ABBV) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.At 10:04 AM EST on November 12, ABBV triggered a Power Inflow signal at a price of...
11/12 12:56 EST - zacks.com
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
11/12 08:30 EST - globenewswire.com
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to...
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to...
11/12 08:30 EST - prnewswire.com
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories - Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum...
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories - Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum...
11/11 22:40 EST - seekingalpha.com
AbbVie Has Many Bullish Attributes (Technical Analysis)
AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and boasts a promising drug pipeline with strong Skyrizi and Rinvoq sales. Technically, ABBV trades...
AbbVie Has Many Bullish Attributes (Technical Analysis)
AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and boasts a promising drug pipeline with strong Skyrizi and Rinvoq sales. Technically, ABBV trades...
11/11 10:50 EST - fool.com
Three Healthcare Buys That Wall Street Loves
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
Three Healthcare Buys That Wall Street Loves
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
11/11 08:49 EST - fool.com
5 Top Stocks to Buy in November
As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all this into consideration and dive into five top stocks I believe could be great additions to your...
5 Top Stocks to Buy in November
As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all this into consideration and dive into five top stocks I believe could be great additions to your...
11/09 11:05 EST - fool.com
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.
Skyrizi and Rinvoq sales are pushing AbbVie's sales higher. UnitedHealth Group raised its full-year guidance and is rebounding from a disastrous 2025.
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.
Skyrizi and Rinvoq sales are pushing AbbVie's sales higher. UnitedHealth Group raised its full-year guidance and is rebounding from a disastrous 2025.
11/09 04:21 EST - fool.com
Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now
The stocks listed here trade at forward price-to-earnings multiples of less than 20. They have underrated growth prospects, which could set them up for better-than-expected gains in the long run.
Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now
The stocks listed here trade at forward price-to-earnings multiples of less than 20. They have underrated growth prospects, which could set them up for better-than-expected gains in the long run.
Market News
×
Loading news…